Successful ibrutinib treatment for central nervous system relapse of chronic lymphocytic leukemia after allogeneic hematopoietic stem cell transplantation

Ann Hematol. 2022 Mar;101(3):723-724. doi: 10.1007/s00277-021-04586-w. Epub 2021 Jul 8.

Authors

Affiliations

¹ Division of Hematology, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.
² Division of Hematology, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan. sakurai@z5.keio.jp.

PMID: 34235557
DOI: 10.1007/s00277-021-04586-w

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adenine / analogs & derivatives*
Adenine / therapeutic use
Adult
Central Nervous System Neoplasms / therapy*
Hematopoietic Stem Cell Transplantation
Humans
Leukemia, Lymphocytic, Chronic, B-Cell / therapy*
Male
Neoplasm Recurrence, Local / therapy*
Piperidines / therapeutic use*
Protein Kinase Inhibitors / therapeutic use*
Transplantation, Homologous
Treatment Outcome
Young Adult

Substances

Piperidines
Protein Kinase Inhibitors
ibrutinib
Adenine